Wegovy vs. Zepbound: Full Cost Comparison (2025)

When patients ask "which is cheaper — Wegovy or Zepbound?" the honest answer is: it depends on your insurance status, the pharmacy you use, and whether you qualify for manufacturer savings programs. The sticker prices are almost never what anyone actually pays — and the gap between list price and actual out-of-pocket cost can be thousands of dollars per year.

This guide walks through every cost layer so you can build a realistic 12-month budget before starting treatment.

Retail Prices at Major Pharmacies

List prices without any insurance or savings programs, as of early 2025:

Drug	Dose	List Price/Month	CVS	Walgreens	Costco
Wegovy (semaglutide)	0.25 mg	~$1,349	~$1,349	~$1,349	~$1,295
Wegovy (semaglutide)	2.4 mg (max)	~$1,349	~$1,349	~$1,349	~$1,295
Zepbound (tirzepatide)	2.5 mg	~$1,059	~$1,059	~$1,059	~$1,020
Zepbound (tirzepatide)	15 mg (max)	~$1,059	~$1,059	~$1,059	~$1,020

Key observation: Zepbound has a list price approximately $290/month lower than Wegovy — roughly $3,480/year less at retail. But retail pricing is almost never the final number.

One important note: Eli Lilly offers Zepbound in single-dose vials (not auto-injector pens) directly through LillyDirect at dramatically reduced prices: $399/month for doses up to 7.5 mg and $549/month for 10 mg and 15 mg. These require a prescription but no insurance. This is currently the lowest-cost branded tirzepatide option available and represents a genuinely transformative price point for cash-pay patients.

Insurance Coverage Odds

Insurance coverage for obesity medications remains inconsistent and is the single largest variable in cost determination.

Wegovy (Semaglutide 2.4 mg)

• Commercial insurance: Covered by approximately 50–60% of employer-sponsored plans that include obesity medication benefits. Coverage has expanded significantly since 2021 but is still not universal.
• Medicare: Covered under Part D for patients with diagnosed cardiovascular disease (following the SELECT trial's cardiovascular risk reduction findings, CMS approved this in 2024). Coverage for obesity alone remains limited under Medicare.
• Medicaid: Coverage varies dramatically by state — approximately 20 states currently cover Wegovy for Medicaid beneficiaries.
• Prior authorization requirements: Almost always required. Typical PA criteria: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, T2D, sleep apnea, dyslipidemia). Documentation of prior lifestyle intervention for 3–6 months is commonly required.

Zepbound (Tirzepatide)

• Commercial insurance: Coverage rates are slightly lower than Wegovy (40–55%) due to Zepbound being newer and some insurers not yet having updated their formularies. This gap is narrowing rapidly.
• Medicare: Not yet covered for obesity alone as of early 2025. Mounjaro (tirzepatide for T2D) is covered under Medicare Part D for patients with diabetes.
• Medicaid: Coverage is even more limited than Wegovy and varies significantly by state.
• PA requirements: Similar to Wegovy — BMI criteria plus comorbidities, lifestyle documentation.

With insurance, both drugs can cost as little as $0–$50/month after manufacturer savings programs are applied to remaining copays — making the coverage question far more important than the list price.

Manufacturer Savings Programs

Novo Nordisk (Wegovy) — NovoCare Savings Card

• Commercially insured: Copay card available; most patients pay $0/month if their insurance covers Wegovy. Maximum savings: $500/month.
• Uninsured / coverage denied: Patient Assistance Program (PAP) available for patients below certain income thresholds. At full income qualification, Wegovy can be provided free. Partial assistance available on a sliding scale.
• Self-pay: No direct Novo Nordisk self-pay discount analogous to LillyDirect. Patients without insurance pay near list price unless using telehealth compounded options.

Eli Lilly (Zepbound) — Lilly Savings Card + LillyDirect

• Commercially insured: Savings card reduces copay; most patients pay $25–$150/month depending on plan deductible status.
• Uninsured: Lilly has implemented a self-pay program through LillyDirect at $399–$549/month for vial formulations — a genuine retail innovation that gives uninsured patients meaningful access.
• Income-based assistance: Lilly Cares Foundation offers free medication to qualifying patients below 400% of the federal poverty level.

Winner for uninsured patients: Zepbound, by a significant margin — the LillyDirect $399/month starting dose is the most accessible branded weight-loss medication pricing currently on the market.

Telehealth Pricing: How Truventa Compares

Telehealth platforms have disrupted obesity medication pricing by offering compounded semaglutide and tirzepatide at significantly lower prices than brand-name alternatives. Important context:

• The FDA placed compounded semaglutide and tirzepatide on shortage lists, which permitted compounding pharmacies to produce them legally. As of 2025, the FDA has taken enforcement actions against some compounders and issued guidance — the regulatory landscape is evolving.
• At Truventa, our physicians prescribe FDA-approved brand-name medications (Wegovy, Zepbound) whenever covered by insurance, and work with patients on savings programs to minimize out-of-pocket costs.
• Telehealth eliminates the cost and time burden of in-person specialist visits, which at obesity medicine practices typically run $200–$400 per visit without insurance.

Truventa pricing model:

• Initial consultation: Included in membership
• Monthly provider follow-up: Included
• Prescription assistance and prior authorization support: Included
• Labs coordination: Included (patient pays lab fees, typically $30–$80 through our partner labs)

This bundled model eliminates the specialist visit cost that traditional obesity medicine practices add to the medication price — typically saving patients $150–$300/month in visit fees alone.

Hidden Costs: Labs and Follow-Ups

Most cost comparisons focus only on the drug price — and miss the supporting costs that make treatment clinically responsible. Before starting either medication, standard baseline labs include:

• Comprehensive metabolic panel (CMP): $15–$40
• Complete blood count (CBC): $10–$30
• HbA1c: $15–$35
• Fasting lipid panel: $15–$30
• TSH (thyroid — important given both drugs' GI effects and thyroid C-cell precaution labeling): $20–$45
• Amylase/lipase (baseline pancreatic function): $20–$40

Total baseline labs: approximately $95–$220 at cash-pay lab pricing (Quest, LabCorp, or Truventa's lab partners).

Follow-up labs at 3, 6, and 12 months are typically a subset (metabolic panel, HbA1c, lipids): approximately $40–$80/visit.

Annual lab cost: $215–$460 depending on baseline needs and follow-up frequency.

If using a traditional endocrinologist or obesity medicine specialist for prescribing:

• Initial visit: $200–$400
• Follow-up visits (quarterly): $100–$200 each = $300–$600/year

Annual specialty care cost (traditional model): $500–$1,000 on top of medication

12-Month Total Cost of Care

Scenario	Wegovy/Year	Zepbound/Year	Notes
Good commercial insurance, savings card	$0–$600	$300–$1,800	Wegovy often $0 with copay card; Zepbound varies more
Insurance denied, self-pay (brand name)	~$16,188	$4,788–$6,588 (LillyDirect)	Massive Zepbound advantage for cash-pay patients
Uninsured, income-based assistance	$0 (PAP)	$0 (Lilly Cares)	Both drugs available free with income qualification
Telehealth + compounded (where available)	$2,400–$4,800	$2,400–$4,800	Regulatory status evolving; discuss with provider

Add $250–$500 for labs and $0–$1,000 for provider visits depending on care model.

Prior Auth Tips: How to Get Approved

Prior authorization denials are the most common reason patients don't start obesity medication — and most denials can be appealed successfully with the right documentation.

• Get your BMI documented formally: Height and weight must appear in your medical record, not just be self-reported.
• Document comorbidities explicitly: Hypertension, sleep apnea, prediabetes, dyslipidemia, and osteoarthritis are all common PA-qualifying conditions. Ask your provider to list these in the PA request.
• Show prior lifestyle efforts: Most PA requirements include a 3–6 month documented history of lifestyle intervention (diet counseling, exercise program). Brief documentation in a provider note suffices; formal programs are not always required.
• Request peer-to-peer review: If denied, your prescribing physician can request a peer-to-peer call with the insurance company's reviewing physician. Approval rates after peer-to-peer are substantially higher (approximately 60–70% in published data).
• Appeal within 30 days: Federal law requires insurers to respond to standard appeals within 30 days and urgent appeals within 72 hours. Submit all clinical documentation with the appeal.

Which Wins on Value?

The answer genuinely depends on your situation:

• Insured with good Wegovy coverage: Wegovy wins on cost (often $0 with savings card) and is a well-established, proven option.
• Self-pay, no assistance qualification: Zepbound wins decisively via LillyDirect — $4,788–$6,588/year vs. ~$16,188 for Wegovy at retail.
• Insured with moderate coverage: Zepbound's savings card is less generous, but its superior average weight loss means potentially better value per pound lost — though this is a clinical, not purely financial, calculation.
• On telehealth: Cost is similar for both compounded options, but the regulatory landscape matters — ensure your provider is using compliant pharmacies.

The most important first step: verify your insurance benefits before your provider sends the prescription. Call your insurer and ask: "Is tirzepatide (Zepbound) and/or semaglutide (Wegovy) covered under my benefits for obesity? What are the prior authorization criteria?" Getting this information upfront avoids the surprise of a pharmacy denial — and helps you and your provider choose the drug most likely to be approved for your specific plan.

Cost is real and it matters — but it shouldn't be the only factor. These medications produce clinically meaningful weight loss that reduces long-term costs of cardiovascular disease, diabetes, sleep apnea, and joint replacement. The return on investment, when you account for downstream healthcare cost reduction, is substantial.

Long-Term Cost of Care: The Bigger Picture

Medication cost comparisons often miss the downstream savings from successful weight loss treatment. Published health economic analyses put the long-term cost savings in perspective:

• Type 2 diabetes prevention: The American Diabetes Association estimates annual care costs for a patient with T2D at $16,752/year — versus $5,389/year for a non-diabetic. A 10% body weight reduction reduces progression from prediabetes to T2D by 58% (Diabetes Prevention Program, NEJM 2002). Even at $1,059/month, preventing diabetes for a decade represents tens of thousands in avoided costs.
• Cardiovascular events: The SELECT trial (NEJM, 2023) demonstrated that semaglutide 2.4 mg reduced major cardiovascular events by 20% in obese patients with established cardiovascular disease. A single hospitalization for myocardial infarction averages $22,000–$47,000 in the US.
• Sleep apnea resolution: The SURMOUNT-OSA trial (NEJM, 2024) found that tirzepatide reduced sleep apnea severity by 55–63%. CPAP equipment and supplies average $1,000–$2,000/year; the associated cardiovascular risk reduction is valued at multiples of that.
• Joint replacement avoidance: Total knee replacement averages $30,000–$50,000 and is strongly associated with obesity. A 15–20% weight reduction significantly reduces both indication rate and surgical risk.

This framing recontextualizes the medication cost: for patients at high metabolic risk, these drugs are not just cosmetic weight-loss interventions — they are disease-modifying therapies with economic returns that dwarf their monthly price.

What Happens When You Stop?

One of the most important cost considerations is often not discussed: both Wegovy and Zepbound require ongoing use to maintain their effects. Multiple discontinuation studies have documented significant weight regain when GLP-1 medications are stopped:

• STEP 4 trial (NEJM, 2021): After 20 weeks of semaglutide, patients randomized to placebo regained an average of 6.9% of body weight over the next 48 weeks while those continuing semaglutide continued to lose weight.
• SURMOUNT-4 (JAMA, 2023): After 36 weeks of tirzepatide, patients switched to placebo regained 14% of body weight over 52 weeks; those continuing tirzepatide maintained losses.

This means the true "cost" of these medications includes the ongoing commitment — and patients should plan budgets accordingly. "Starting and stopping" based on short-term financial pressures is the most expensive approach in the long run, as it incurs drug costs without sustaining the health benefits.

If long-term affordability is a concern, discuss this explicitly with your provider before starting. Planning for cost sustainability — which may involve locking in savings programs, securing insurance coverage, or choosing Zepbound's LillyDirect vials — is part of responsible treatment planning, not a secondary consideration.

Questions to Ask Before Starting

Before your first prescription is submitted, make sure you can answer these questions:

1. Does my insurance cover this drug? (Call member services with the NDC number of the specific drug)
2. What are the prior authorization criteria for my plan?
3. Am I eligible for the manufacturer savings card? (Both have income requirements that exclude very high earners)
4. Is my pharmacy in-network for specialty medications? (Many specialty drugs must go through specific pharmacies)
5. What's my deductible status? (If you haven't met your deductible, you pay full cost until you do — often $1,000–$3,000 in January and February)
6. What is the appeal process if I'm denied?

A Truventa provider can help coordinate prior authorization, appeal processes, and savings card activation — reducing the administrative burden that causes many patients to abandon treatment before it starts. The medication works; getting past the administrative barriers is often the hardest part.